
Autolus Therapeutics plc AUTL
€ 1.23
-5.88%
Quartalsbericht 2025-Q3
hinzugefügt 25.04.2026
Autolus Therapeutics plc Langfristiger Schuldenstrom 2011-2026 | AUTL
Langfristiger Schuldenstrom Jährlich Autolus Therapeutics plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.56 M | 3 M | 5.05 M | 5.04 M | - | 3.59 M | 2.51 M | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 5.05 M | 2.51 M | 3.96 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
23 K | - | -19.68 % | $ 18.4 M | ||
|
Aptorum Group Limited
APM
|
433 K | $ 0.9 | -2.33 % | $ 6.62 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
9.96 M | $ 21.96 | -0.68 % | $ 3.64 B | ||
|
RedHill Biopharma Ltd.
RDHL
|
353 K | $ 1.02 | -0.49 % | $ 428 M | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Aligos Therapeutics
ALGS
|
3.58 M | $ 6.4 | 4.4 % | $ 63.3 M | ||
|
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Aridis Pharmaceuticals
ARDS
|
538 K | - | 17.91 % | $ 11.1 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 21.41 | 1.9 % | $ 1 B | ||
|
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
208 K | - | -2.5 % | $ 5.88 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
BioNTech SE
BNTX
|
45 M | $ 105.46 | -0.09 % | $ 27.2 B | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
631 K | $ 4.08 | 0.25 % | $ 436 M | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 23.26 | 1.75 % | $ 2.96 B | ||
|
Cara Therapeutics
CARA
|
116 K | - | -3.03 % | $ 260 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
BioXcel Therapeutics
BTAI
|
65 K | $ 1.06 | -3.64 % | $ 12.9 M | ||
|
CASI Pharmaceuticals
CASI
|
1.06 M | - | - | $ 35.4 M | ||
|
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | ||
|
Cabaletta Bio
CABA
|
3.46 M | $ 2.95 | -3.28 % | $ 296 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 2.91 | -1.36 % | $ 4.79 M | ||
|
bluebird bio
BLUE
|
21.2 M | - | - | $ 546 M | ||
|
CymaBay Therapeutics
CBAY
|
7 K | - | - | $ 3.45 B |